BNP Paribas Arbitrage SA increased its position in LHC Group, Inc. (NASDAQ:LHCG) by 54.0% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,662 shares of the health services provider’s stock after purchasing an additional 3,037 shares during the period. BNP Paribas Arbitrage SA’s holdings in LHC Group were worth $614,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of LHCG. Nine Chapters Capital Management LLC bought a new stake in shares of LHC Group during the third quarter valued at approximately $255,000. Bessemer Group Inc. raised its holdings in LHC Group by 17.2% during the third quarter. Bessemer Group Inc. now owns 20,400 shares of the health services provider’s stock worth $1,447,000 after purchasing an additional 3,000 shares in the last quarter. Smith Asset Management Group LP bought a new stake in LHC Group during the third quarter worth approximately $1,421,000. Great West Life Assurance Co. Can raised its holdings in LHC Group by 3.7% during the second quarter. Great West Life Assurance Co. Can now owns 22,229 shares of the health services provider’s stock worth $1,508,000 after purchasing an additional 790 shares in the last quarter. Finally, State Street Corp raised its holdings in LHC Group by 7.5% during the second quarter. State Street Corp now owns 420,839 shares of the health services provider’s stock worth $28,568,000 after purchasing an additional 29,464 shares in the last quarter. Institutional investors and hedge funds own 85.41% of the company’s stock.
Several brokerages recently commented on LHCG. SunTrust Banks reissued a “buy” rating and set a $75.00 target price on shares of LHC Group in a report on Friday, November 3rd. Zacks Investment Research lowered shares of LHC Group from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Oppenheimer lifted their price target on shares of LHC Group from $68.00 to $80.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 7th. Craig Hallum reiterated a “buy” rating and set a $80.00 price objective (up from $67.00) on shares of LHC Group in a research report on Tuesday, November 7th. Finally, Royal Bank of Canada lifted their price objective on shares of LHC Group from $70.00 to $81.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. LHC Group currently has a consensus rating of “Buy” and an average target price of $77.10.
LHC Group (NASDAQ:LHCG) last released its earnings results on Monday, November 6th. The health services provider reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.60 by $0.04. The firm had revenue of $272.90 million during the quarter, compared to analyst estimates of $265.35 million. LHC Group had a net margin of 4.09% and a return on equity of 9.52%. The business’s revenue was up 18.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.54 EPS. analysts forecast that LHC Group, Inc. will post 2.4 earnings per share for the current year.
LHC Group Company Profile
LHC Group, Inc is a holding company. The Company provides post-acute healthcare services to patients through its home nursing agencies, hospice agencies, community-based services agencies and long-term acute care hospitals (LTACHs). The Company operates through four segments: home health services, hospice services, community-based services and facility-based services.
Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.